AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry?

Why it matters

AbbVie's $8 billion debt raise for an acquisition is a sizable but routine corporate financing event typical in large-cap M&A activity, unlikely to alter credit market structure or underwriting standards materially.

Sources

• The Motley Fool

  AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry?

  The pharmaceutical company hopes that another big-time acquisition will pay off.

• Yahoo Finance

  AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry?

• Nasdaq

  AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry?

  Key PointsAbbVie has been willing to supplement its new drug pipeline through acquisitions.